No Hat Trick For Roche's Gazyva In Lymphoma

Roche's Gazyva/Gazyvaro missed its primary endpoint in a Phase III study in first-line diffuse large B-cell lymphoma, failing to score a treble in lymphoma indications for the product, which the company is relying on to replace revenues from the increasingly biosimilared rituximab. The failure has also brought to investors' minds the larger uncertainty over Perjeta's future in breast cancer in the APHINITY study.